UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.
UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.